User contributions for Aidan

19:5219:52, 3 October 2025 diff hist +447 N CR:DOI:0c5083d354004ce136f5a154d1a82809 Created page with "{{#scite: |reference=janda2016pl |type=journal-article |title=Plesiomonas shigelloides Revisited |author=J. Michael Janda;Sharon L. Abbott;Christopher J. McIver|+sep=; |journal=Clinical Microbiology Reviews |publisher=American Society for Microbiology |year=2016 |volume=29 |issue=2 |pages=349-374 |doi=10.1128/cmr.00103-15 |issn=0893-8512;1098-6618|+sep=; |retrieved-from=https://dx.doi.org/ |retrieved-on=2025-10-03 |@show=true }}" current
19:4219:42, 3 October 2025 diff hist +105 Stevens-Johnson syndrome No edit summary Tag: Visual edit
15:5915:59, 3 October 2025 diff hist +101 Solobacterium moorei No edit summary current Tag: Visual edit
15:5815:58, 3 October 2025 diff hist +667 N Solobacterium moorei Created page with "== Background == * Non-spore-forming strictly anaerobic Stain::Gram-positive Shape::bacillus * Typically isolated from human feces and difficult to cluster == Clinical Manifestations == * Associated with halitosis and odontogenic infections * Rare bacteremia, particularly in immunocompromised peopleCiteRef::detry2006se CiteRef::pedersen2011so * Rare wound infections == Management == * Appears to be generally susceptible to most antibiotics, including..." Tag: Visual edit
15:5815:58, 3 October 2025 diff hist +530 N CR:DOI:38c0b6c9e2d1528222521e987cd84f7e Created page with "{{#scite: |reference=pedersen2011so |type=journal-article |title=Solobacterium moorei Bacteremia: Identification, Antimicrobial Susceptibility, and Clinical Characteristics |author=Rune Micha Pedersen;Hanne Marie Holt;Ulrik Stenz Justesen|+sep=; |journal=Journal of Clinical Microbiology |publisher=American Society for Microbiology |year=2011 |volume=49 |issue=7 |pages=2766-2768 |doi=10.1128/jcm.02525-10 |issn=0095-1137;1098-660X|+sep=; |retrieved-from=https:..." current
15:5815:58, 3 October 2025 diff hist +592 N CR:DOI:804c4fe07b0de921b874dc6256d3ef72 Created page with "{{#scite: |reference=zheng2010ph |type=journal-article |title=Phenotypic and Molecular Characterization of Solobacterium moorei Isolates from Patients with Wound Infection |author=Guili Zheng;Paula H. Summanen;David Talan;Robert Bennion;Marie-Claire Rowlinson;Sydney M. Finegold|+sep=; |journal=Journal of Clinical Microbiology |publisher=American Society for Microbiology |year=2010 |volume=48 |issue=3 |pages=873-876 |doi=10.1128/jcm.0138..." current
15:5715:57, 3 October 2025 diff hist +453 N CR:DOI:b5baff6ee77428ce0cca0b97b362d58c Created page with "{{#scite: |reference=detry2006se |type=journal-article |title=Septicemia due to Solobacterium moorei in a patient with multiple myeloma |author=G. Detry;D. Pierard;K. Vandoorslaer;G. Wauters;V. Avesani;Y. Glupczynski|+sep=; |journal=Anaerobe |publisher=Elsevier BV |year=2006 |volume=12 |issue=3 |pages=160-162 |doi=10.1016/j.anaerobe.2006.04.002 |issn=1075-9964 |retrieved-from=https://dx.doi.org/ |retrieved-on=2025-10-03 |@show=true }}" current
14:4214:42, 3 October 2025 diff hist +672 WBC scan No edit summary current Tag: Visual edit

16:1316:13, 2 October 2025 diff hist +55 Mycobacterium bovis (BCG strain) No edit summary Tag: Visual edit
16:1216:12, 2 October 2025 diff hist +46 N BCG infection Aidan moved page BCG infection to Mycobacterium bovis (BCG strain) current Tag: New redirect
16:1216:12, 2 October 2025 diff hist 0 m Mycobacterium bovis (BCG strain) Aidan moved page BCG infection to Mycobacterium bovis (BCG strain)
16:1216:12, 2 October 2025 diff hist +1,049 N Mycobacterium bovis (BCG strain) Created page with "== Background == * Intravesicular instillation is used to treat bladder cancer == Clinical Manifestations == * Median time from instillation to onset of symptoms is Incubation period::169 days CiteRef::cabas2021bc (range 3 months to many years) * Disease can disseminate to liver, lungs, bone marrow, bones, joints (in descending order of frequency) * Localized disease can cause cystitis, bladder contractures, granulomatous prostatitis, prostate abscess, epid..." Tag: Visual edit
16:0416:04, 2 October 2025 diff hist +634 N CR:DOI:7b11983fdb4b47719c755d94414b8105 Created page with "{{#scite: |reference=cabas2021bc |type=journal-article |title=BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: A systematic review |author=Paolo Cabas;Michele Rizzo;Mauro Giuffrè;Roberta Maria Antonello;Carlo Trombetta;Roberto Luzzati;Giovanni Liguori;Stefano Di Bella|+sep=; |journal=Urologic Oncology: Seminars and Original Investigations |publisher=Elsevier BV |year=2021 |volume..." current
15:3515:35, 2 October 2025 diff hist +81 Pembrolizumab No edit summary current Tag: Visual edit
15:3315:33, 2 October 2025 diff hist +57 N Padcev Redirected page to Enfortumab vedotin current Tags: New redirect Visual edit
15:3215:32, 2 October 2025 diff hist +604 N Enfortumab vedotin Created page with "* Antibody-drug conjugate targeting Nectin-4 that is present on the surface of most urothelial cancer cells * Indicated for urothelial cancer * Common adverse effects include: rashes (about 50%, can be severe), alopecia (in about 50%); abdominal pain, anorexia, constipation, diarrhea, and nausea/vomiting; fatigue; myelosuppression; myalgias; dysgeusia; peripheral neuropathy (in about 50%, can be severe); dry eyes ** Also liver enzyme abnormalities, insomnia, hypergly..." current Tag: Visual edit
15:2915:29, 2 October 2025 diff hist +32 N Enfortumab Redirected page to Enfortumab vedotin current Tags: New redirect Visual edit
15:0215:02, 2 October 2025 diff hist +25 Clostridioides difficile No edit summary Tag: Visual edit
15:0215:02, 2 October 2025 diff hist +550 N CR:DOI:d14017def84fc22da503fdd490bb0b3a Created page with "{{#scite: |reference=miller2023co |type=journal-article |title=Comparison of Different Antibiotics and the Risk for Community-Associated Clostridioides difficile Infection: A Case–Control Study |author=Aaron C Miller;Alan T Arakkal;Daniel K Sewell;Alberto M Segre;Joseph Tholany;Philip M Polgreen;|+sep=; |journal=Open Forum Infectious Diseases |publisher=Oxford University Press (OUP) |year=2023 |volume=10 |issue=8 |doi=10.1093/ofid/ofad413 |issn=2328-8957 |r..." current
15:0115:01, 2 October 2025 diff hist +460 Clostridioides difficile No edit summary Tag: Visual edit
15:0015:00, 2 October 2025 diff hist +567 N CR:DOI:484c0725a5f4bd4d826b3f1321b5686d Created page with "{{#scite: |reference=liu2024ri |type=journal-article |title=Risk of Clostridioides difficile infection following different antibiotics: insights from multi-source medical data |author=Yangxi Liu;Mengfei Dai;Kanghuai Zhang;Li Zhang;Bin Lin;Keyu Chen;Haitao Wang;Zhichun Gu;Yuetian Yu;Yan Wang|+sep=; |journal=International Journal of Antimicrobial Agents |publisher=Elsevier BV |year=2024 |volume=64 |issue=4 |pages=107288 |doi=10.1016/j.ijantimicag.2024.107288 |i..." current
14:5814:58, 2 October 2025 diff hist +561 N CR:DOI:1ec3e49d4680d8d915977fc8bb2ee8c4 Created page with "{{#scite: |reference=gilboa2025an |type=journal-article |title=Antibiotic Use and the Risk of Hospital-Onset Clostridioides Difficile Infection |author=Mayan Gilboa;Gili Regev-Yochay;Eyal Meltzer;Ido Cohen;Yovel Peretz;Tal Zilberman-Daniels;Amitai Segev;Sharon Amit;Dafna Yahav;Noam Barda|+sep=; |journal=JAMA Network Open |publisher=American Medical Association (AMA) |year=2025 |volume=8 |issue=8 |pages=e2525252 |doi=10.1001/jamanetworkopen.2025.25252 |issn=25..." current
14:3814:38, 2 October 2025 diff hist +328 Clostridioides difficile No edit summary Tag: Visual edit
14:3614:36, 2 October 2025 diff hist +518 N CR:DOI:415d00cc0f165bd9079d5acf07764747 Created page with "{{#scite: |reference=phillips2022im |type=journal-article |title=Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study |author=Emma C. Phillips;Cirle A. Warren;Jennie Z. Ma;Gregory R. Madden|+sep=; |journal=Antimicrobial Agents and Chemotherapy |publisher=American Society for Microbiology |year=2022 |volume=66 |issue=6 |doi=10.1128/aac.00001-22 |issn=0066-4804;1098-6596|+sep=; |retrieved-from=https://dx.doi.org..." current
14:2914:29, 2 October 2025 diff hist +436 N CR:DOI:877d53e0da2abb06283993a9959f1ac8 Created page with "{{#scite: |reference=heleno2021fi |type=journal-article |title=Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection |author=Caio T Heleno;Aleksey Tagintsev;Katharine Lasley;Douglas Summerfield|+sep=; |journal=Cureus |publisher=Springer Science and Business Media LLC |year=2021 |doi=10.7759/cureus.16559 |issn=2168-8184 |retrieved-from=https://dx.doi.org/ |retrieved-on=2025-10-02 |@show=true }}" current

19:0519:05, 30 September 2025 diff hist +4 m Anaplasma phagocytophilum →Clinical Manifestations current
18:3418:34, 30 September 2025 diff hist −26 m Leptospira →Clinical Manifestations current Tag: Visual edit
18:2718:27, 30 September 2025 diff hist −3 m Kawasaki disease →Diagnostic Criteria current
16:1516:15, 30 September 2025 diff hist +42 Prosthetic joint infection →Antimicrobial Therapy current Tag: Visual edit

20:4620:46, 29 September 2025 diff hist +905 N Drug-induced thrombocytopenia Created page with "* Typical onset 5 to 10 days after drug administration ** Nadir of less than 20 ** A severe form is heparin-induced thrombocytopenia, discussed elsewhere ** Counts usually start to recover after 4 or 5 half-lives of the offending medication * IVIG can be given in severe thrombocytopenia * Drugs associated with non-immune thrombocytopenia ** Impaired thrombopoiesis: chemotherapy, interferon-alpha, linezolid, botrezomib, thiazide diuretics, ethanol, tolbutamid, g..." current Tag: Visual edit
18:3718:37, 29 September 2025 diff hist +287 Golimumab No edit summary current Tag: Visual edit
18:3518:35, 29 September 2025 diff hist +187 N Golimumab Created page with "* Humanized monoclonal antibody targeting TNF * Indications including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis Category:Monoclonal antibodies" Tag: Visual edit

14:3014:30, 24 September 2025 diff hist +42 Granulomatous disease No edit summary current Tag: Visual edit

14:1114:11, 19 September 2025 diff hist +753 N Central venous access device-related upper extremity deep vein thrombosis Created page with " == Management == * Anticoagulation * If CVAD still needed: continue anticoagulation while it is in situ * If CVAD no longer needed: ** If it can be left in situ, leave it for up to 3-5 days, up to 7 days, while on anticoagulation to reduce risk of embolism ** Continue anticoagulation for 3 months * Choice of anticoagulation is primarily LMWH == Prevention == * Use small calibre catheter possible * Ensure proper catheter tip location * Remove CVADs when no longer..." current Tag: Visual edit
14:0614:06, 19 September 2025 diff hist +87 N PICC-associated DVT Redirected page to Central venous access device-related upper extremity deep vein thrombosis current Tags: New redirect Visual edit
04:0104:01, 19 September 2025 diff hist −23 m Tuberculous adenitis No edit summary current
04:0104:01, 19 September 2025 diff hist 0 m Tuberculous adenitis No edit summary
03:5403:54, 19 September 2025 diff hist +51 Tuberculous adenitis No edit summary Tag: Visual edit
03:5403:54, 19 September 2025 diff hist +472 N CR:DOI:93a20281efae8df25b04c217a2b9e759 Created page with "{{#scite: |reference=hermans2024po |type=journal-article |title=Post-tuberculosis treatment paradoxical reactions |author=Sabine M. Hermans;Onno W. Akkerman;Graeme Meintjes;Martin P. Grobusch|+sep=; |journal=Infection |publisher=Springer Science and Business Media LLC |year=2024 |volume=52 |issue=5 |pages=2083-2095 |doi=10.1007/s15010-024-02310-0 |issn=0300-8126;1439-0973|+sep=; |retrieved-from=https://dx.doi.org/ |retrieved-on=2025-09-19 |@show=true }}" current
03:5203:52, 19 September 2025 diff hist +178 Tuberculous adenitis No edit summary Tag: Visual edit
03:5103:51, 19 September 2025 diff hist +579 N CR:DOI:3917348f8490a2874a73be4769774c60 Created page with "{{#scite: |reference=hawkey2005ch |type=journal-article |title=Characterization and Management of Paradoxical Upgrading Reactions in HIV-Uninfected Patients with Lymph Node Tuberculosis |author=C. R. Hawkey;T. Yap;J. Pereira;D. A. J. Moore;R. N. Davidson;G. Pasvol;O. M. Kon;R. A. Wall;R. J. Wilkinson|+sep=; |journal=Clinical Infectious Diseases |publisher=Oxford University Press (OUP) |year=2005 |volume=40 |issue=9 |pages=1368-1371 |doi=10.1086/429317 |issn=1..." current
03:4903:49, 19 September 2025 diff hist +516 N CR:DOI:5d6fdd1fb4d601ac3b859435236fe3d1 Created page with "{{#scite: |reference=van loenhout-rooyackers2000sh |type=journal-article |title=Shortening the duration of treatment for cervical tuberculous lymphadenitis |author=JH van Loenhout-Rooyackers;RJ Laheij;C Richter;AL Verbeek|+sep=; |journal=European Respiratory Journal |publisher=European Respiratory Society (ERS) |year=2000 |volume=15 |issue=1 |pages=192-195 |doi=10.1183/09031936.00.15119200 |issn=0903-1936;1399-3003|+sep=; |retrieved-from=https://dx.doi.org/..." current
03:3003:30, 19 September 2025 diff hist −901 m CR:PMID:20074418 No edit summary current
03:2903:29, 19 September 2025 diff hist +145 Recurrent tuberculosis No edit summary current Tag: Visual edit
03:2903:29, 19 September 2025 diff hist +550 N CR:DOI:13a597f6f29e1c215a69fc2351732611 Created page with "{{#scite: |reference=vega2024ri |type=journal-article |title=Risk factors for pulmonary tuberculosis recurrence, relapse and reinfection: a systematic review and meta-analysis |author=Victor Vega;Javier Cabrera-Sanchez;Sharon Rodríguez;Kristien Verdonck;Carlos Seas;Larissa Otero;Patrick Van der Stuyft|+sep=; |journal=BMJ Open Respiratory Research |publisher=BMJ |year=2024 |volume=11 |issue=1 |pages=e002281 |doi=10.1136/bmjresp-2023-002281 |issn=2052-4439 |r..." current
03:2603:26, 19 September 2025 diff hist −12 CR:PMID:20074418 No edit summary
03:2503:25, 19 September 2025 diff hist +503 N Recurrent tuberculosis Created page with "* Recurrence of TB infection, either as relapse of initial infection (around 80% of recurrences in low-endemic settingsCiteRef::vega2021re) or reinfection (more common in regions with endemic TB) * Occurs at a rate of about 2.26 per 100 person years at riskCiteRef::vega2021re * Typically occurs during first 2 years ** Relapses in susceptible TB mostly occur during first 6 months (78%) and almost always during first 12 months (91%) of therapy[[CiteRef::nunn2010ti]..." Tag: Visual edit
03:2503:25, 19 September 2025 diff hist +23 CR:PMID:20074418 No edit summary
03:2503:25, 19 September 2025 diff hist +1,443 N CR:PMID:20074418 Created page with "{{#scite:PMID20074418 |type=Journal Article |title=Timing of relapse in short-course chemotherapy trials for tuberculosis. |author=Nunn AJ;Phillips PP;Mitchison DA|+sep=; |journal=The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease |iso-abbreviation=Int J Tuberc Lung Dis |pubdate=2010 Feb |year=2010 |volume=14 |issue=2 |pages=241-2 |abstract=We have reviewed the resu..."
03:2003:20, 19 September 2025 diff hist +514 N CR:DOI:2c78080545901114e8b6601446040655 Created page with "{{#scite: |reference=vega2021re |type=journal-article |title=Recurrent TB: a systematic review and meta-analysis of the incidence rates and the proportions of relapses and reinfections |author=Victor Vega;Sharon Rodríguez;Patrick Van der Stuyft;Carlos Seas;Larissa Otero|+sep=; |journal=Thorax |publisher=BMJ |year=2021 |volume=76 |issue=5 |pages=494-502 |doi=10.1136/thoraxjnl-2020-215449 |issn=0040-6376;1468-3296|+sep=; |retrieved-from=https://dx.doi.org/ |..." current

User contributions for Aidan

3 October 2025

2 October 2025

30 September 2025

29 September 2025

24 September 2025

19 September 2025